Aquilo Partners Research
Advisory Approach
Aquilo Partners is an independent investment bank with a singular, focused mandate: to advise life science innovators on the most complex strategic and financial transactions in healthcare. Founded in 2002 and headquartered in San Francisco with additional offices in New York and Boston, Aquilo operates on the thesis that life science companies require specialized financial advisors who understand the unique dynamics of drug development, clinical trial financing, regulatory pathways, and the strategic rationales that drive pharma and medtech acquisitions.
The firm positions itself as a trusted advisor when life science companies face pivotal moments: raising capital to advance clinical programs, licensing intellectual property to global pharmaceutical partners, or pursuing transformational M&A transactions with strategic buyers and private equity. Aquilo's competitive advantage stems from 20+ years of focused expertise in life sciences, deep relationships with pharmaceutical and medical device companies, and a team of investment bankers who understand the science, regulatory environment, and commercial dynamics of the sector.
Their advisory philosophy centers on three core pillars: (1) analytical groundwork that creates defensible valuations and transaction structures; (2) relationship leverage with key decision makers at pharmaceutical companies and PE firms; and (3) client-focused selectivity—they turn down engagements that don't align with their thesis or where they can't deliver unique value.
Sector Focus and Expertise
Aquilo Partners' practice is exclusively focused on life sciences, spanning three core verticals:
Biopharmaceutical & Therapeutic Companies: This is Aquilo's largest and most active practice. They advise clinical-stage and commercial-stage therapeutic companies across all therapeutic areas—oncology, ophthalmology, gene therapy, immunology, and rare disease. Their deal track record demonstrates particular depth in gene therapy (Adverum to Eli Lilly) and specialty pharma assets (Disarm Therapeutics to Eli Lilly, Protomer to Eli Lilly). The firm understands the full lifecycle of a therapeutic company from Series A through exit or partnership licensing.
Medical Devices & Diagnostics: Aquilo advises medtech and diagnostics companies on acquisitions, partnerships, and financings. Recent transactions include the sale of DURECT's ALZET osmotic pump line to Lafayette Instrument ($17.5M), strategic partnerships for diagnostics companies (PreciseDx Series B), and medtech platform exits. The firm has particular expertise in regulatory capital raise strategies for FDA-regulated medical devices and in-vitro diagnostics (IVDs).
Life Science Tools & Platforms: Aquilo advises life science tool companies and laboratory instrument manufacturers on M&A and partnerships. Swift Bioscience (NGS library preparation kits acquired by Danaher/IDT) and Curio Biosciences (single-cell spatial biology tools to Takara Bio) exemplify this vertical. These companies often serve as enablers to larger pharmaceutical development platforms.
Transaction Experience & Deal Track Record
Aquilo has facilitated over 105 transactions spanning M&A, strategic partnerships, and private capital raises. The firm's deal history reveals several patterns:
M&A Transactions (Recent & Notable):
- Adverum Biotechnologies → Eli Lilly (October 2025): Advised Adverum on the sale of the company and its lead gene therapy candidate (Ixo-vec) for Phase 3 wet age-related macular degeneration. Deal included upfront payment plus CVR contingent on FDA approval and sales milestones. This was a competitive process involving multiple strategic buyers, showcasing Aquilo's ability to run exhaustive processes and command premium valuations.
- Applied Therapeutics → Cycle Pharmaceuticals (February 2026): Provided fairness opinion for Applied Therapeutics on acquisition by Cycle. Applied focused on ultra-rare genetic diseases; Cycle's acquisition integrated Applied's pipeline into a specialized rare disease franchise.
- DURECT → Lafayette Instrument (November 2024): Advised on sale of the ALZET product line (osmotic drug delivery pumps) for $17.5M cash, enabling DURECT to refocus capital and extend cash runway.
- Disarm Therapeutics → Eli Lilly (October 2020): Advised on acquisition of clinical-stage immunology company.
- Protomer Technologies → Eli Lilly (July 2021): M&A advisory on strategic acquisition.
- Swift Bioscience → Danaher/IDT (2023): Sale of NGS library preparation genomics kits company.
- Curio Biosciences → Takara Bio USA: Acquisition of single-cell spatial biology tools platform.
Strategic Partnerships & Licensing (Recent & Notable):
- Matchpoint Therapeutics - Novartis Option Agreement (2024): $1B+ license agreement for oral covalent IRAK4 inhibitors. Aquilo advised on terms and structured the partnership.
- Kymera - Sanofi Partnership (2024): $2.1B+ collaboration agreement to develop and commercialize IRAK4 protein degrader therapies.
- AmacaThera - Pacira Biosciences Exclusive License (November 2025): Up to $230M licensing agreement for drug delivery platform. Aquilo acted as financial advisor.
- Aldeyra - AbbVie Option Agreement (2023): $400M+ to license reproxalap program.
- Matchpoint - Novartis License: Multiple Novartis relationships.
Private Capital Raises:
- PreciseDx Series B ($20.7M, August 2024) — AI-powered cancer risk assessment
- Multiple Series A and Series D preferred stock placements
The breadth and quality of these transactions underscore Aquilo's position as a premier advisor for life science M&A in the $50M–$200M+ range. Their buyer network spans Eli Lilly (repeat acquirer), major pharma (Novartis, Sanofi, AbbVie, GSK, AstraZeneca, Boehringer Ingelheim), medtech leaders (Danaher, Becton Dickinson, Boston Scientific, Medtronic), and specialized platforms (Takara Bio, Exact Sciences). The firm has also advised on acquisitions by private equity firms and strategic capital investors.
Advisory Process & Capabilities
Aquilo operates across the full spectrum of life science advisory services:
M&A Advisory:
- Full sell-side M&A processes (multiple buyer outreach, negotiation, deal structure)
- Buy-side advisory (target identification, valuation, due diligence support)
- Fairness opinions (as seen in the Applied Therapeutics transaction)
- Pro forma analysis and integration synergy modeling
Strategic Partnerships & Licensing:
- Licensing strategy and valuation analysis
- Out-licensing to pharma partners (optimizing economic and non-economic terms)
- In-licensing evaluations and impact modeling
Private Capital Raises:
- Venture capital placements (Series A through Series D+)
- PIPE (Private Investment in Public Equity) structures
- Strategic investor identification and investor relations
Financial Advisory:
- Valuation analysis and fairness opinions
- Strategic financial modeling
- Acquisition integration advisory
The firm's approach emphasizes analytical rigor (detailed financial models and market intelligence), creative deal structuring, and client selectivity. They invest significant time upfront understanding each client's science, competitive positioning, and strategic optionality before proceeding to outreach and negotiations.
Team & Organization
Aquilo Partners operates with approximately 40-50 professionals across San Francisco, Boston, and New York offices. The leadership team includes:
Managing Directors (founders and senior leadership):
- Jim Zanze — Co-founder, Managing Director, San Francisco
- John Dyer — Managing Director, Cambridge, MA area
- David Metzger — Managing Director
- John Rumsey — Managing Director, San Francisco
- Jason Yip — Managing Director
- Ian MacKay — Managing Director
Other Team:
- Kelly Gross — Principal
- Zachary Stabell — Analyst
The team includes investment bankers with 15–25+ years of M&A experience, many with prior roles at larger investment banks (JPMorgan, Goldman Sachs) and operating experience at biotech/pharma companies. Several team members hold FINRA registrations (Series 79, Series 63) and professional certifications (CFA, etc.). The firm maintains a disciplined, focused culture—selective in client engagement and committed to delivering high-quality outputs.
Regulatory Status & Compliance
Aquilo Partners, L.P. is a registered broker-dealer with FINRA (CRD# 114909) and member of SIPC. The firm maintains a Business Continuity Plan and is subject to FINRA and SEC oversight. This regulatory standing enables Aquilo to act as a placement agent for private capital raises and to provide fairness opinions on M&A transactions—critical credentials in institutional advisory.
Geographic Reach & Buyer Network
Aquilo has a global practice serving life science companies across the United States and internationally. The firm explicitly states "Aquilo works for clients around the globe." Its offices in San Francisco, Boston (Cambridge), and New York provide access to key innovation hubs and buyer relationships.
Recurring Strategic & PE Buyers: Based on transaction history, Aquilo maintains strong relationships with:
- Pharmaceutical Corporations: Eli Lilly (4+ transactions as buyer), Novartis, Sanofi, AbbVie, GSK, AstraZeneca, Boehringer Ingelheim, Eisai
- Medical Device & Diagnostics Leaders: Danaher, Becton Dickinson, Boston Scientific, Medtronic, Exact Sciences
- Specialized Life Science Platforms: Takara Bio, TerSera, Ligand, Vertex, Oncternal
- Private Equity & Strategic Investors: Family offices, venture capital, specialized healthcare PE firms
Sweet Spot & Positioning
Aquilo's ideal client is a life science company at a pivotal moment: raising Series B/C/D capital, exploring licensing deals with global pharma, or executing a strategic sale. The firm targets companies with:
- Validated science (clinical data, regulatory approvals, or strong preclinical packages)
- Enterprise values typically in the $50M–$500M+ range
- Defensible intellectual property or market-leading platforms
- Management teams committed to value creation
Competitive Differentiation
Aquilo differentiates from larger, generalist investment banks through:
- Focused Expertise: 20+ years focused exclusively on life sciences—not a subsidiary of a larger firm, not diluted across multiple sectors
- Relationship Network: Direct relationships with key decision makers at pharma and medtech companies, built over decades
- Analytical Depth: Rigorous financial modeling and market intelligence that informs deal structure and valuation
- Selectivity: Willingness to turn down engagements where they can't deliver unique value, ensuring committed partnerships
- Process Rigor: Comprehensive due diligence support, management presentation coaching, and structured buyer outreach
Total Transaction Volume & Aggregate Metrics
According to third-party sources (Tracxn, 2026), Aquilo Partners has facilitated 105+ transactions to date, comprising 51 M&A deals and 54 funding rounds. While individual deal sizes vary, the firm's track record spans from venture-backed Series A placements through multi-hundred-million-dollar M&A exits. The firm does not publicly disclose aggregate transaction value, but based on high-profile exits (Adverum to Lilly, multi-billion-dollar licensing deals), the cumulative transaction value exceeds several billion dollars.
Buyer Network Strength
From deal analysis, Aquilo demonstrates:
- Strategic Pharma Relationships: 60+ transactions with strategic pharmaceutical buyers (Eli Lilly, Novartis, Sanofi, AbbVie, GSK, etc.)
- Medtech & Diagnostic Buyer Access: Strong ties to device and diagnostics consolidators (Danaher, Becton Dickinson, Boston Scientific)
- PE Firm Relationships: Relationships with numerous healthcare-focused private equity firms
- Global Reach: Ability to facilitate international partnerships and cross-border transactions
Assessment
Aquilo Partners is a premier, specialized advisor for life science companies requiring expert guidance on M&A, partnerships, and capital raising. The firm's 20+ year focused track record, deep pharmaceutical relationships, analytical rigor, and selective client approach position it as a trusted partner for companies navigating transformational strategic transactions. For life science founders and executives, Aquilo represents best-in-class advisory in one of the most complex, highest-stakes sectors of investment banking.